Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leyvraz

Showing results (381-390 of 405) with videos related to

Pageof 41
Sort By:
BMC Cancer|June 7, 2022
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinibJames C H Yang, Marcia S Brose, Gilberto Castro, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2022
Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility studySerge Leyvraz, Frank Konietschke, Caroline Peuker, et al.
International Journal of Cancer|February 24, 2006
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysisJacques-Olivier Bay, Isabelle Ray-Coquard, Jérôme Fayette, et al.
European Journal of Cancer (Oxford, England : 1990)|January 27, 2020
Support of a molecular tumour board by an evidence-based decision management system for precision oncologyMario Lamping, Manuela Benary, Serge Leyvraz, et al.
The Oncologist|June 17, 2024
A diagnostic challenge of KIT p.V559D and BRAF p.G469A mutations in a paragastric massStefan Habringer, Jana Ihlow, Karsten Kleo, et al.
Cancer|January 10, 2018
Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07)Michael Montemurro, Angela Cioffi, Julien Dômont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2014
Adjuvant radiotherapy for extremity and trunk wall atypical lipomatous tumor/well-differentiated LPS (ALT/WD-LPS): a French Sarcoma Group (GSF-GETO) studyP A Cassier, G Kantor, S Bonvalot, et al.
Journal for Immunotherapy of Cancer|June 6, 2024
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanomaJoseph J Sacco, Richard D Carvajal, Marcus O Butler, et al.
European Journal of Endocrinology|March 25, 2022
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinomaSteven G Waguespack, Alexander Drilon, Jessica J Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2012
Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor eraPhilippe A Cassier, Elena Fumagalli, Piotr Rutkowski, et al.
Pageof 41

Showing results (381-390 of 405) with videos related to

Sort By:
Pageof 41
BMC Cancer|June 7, 2022
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinibJames C H Yang, Marcia S Brose, Gilberto Castro, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2022
Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility studySerge Leyvraz, Frank Konietschke, Caroline Peuker, et al.
International Journal of Cancer|February 24, 2006
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysisJacques-Olivier Bay, Isabelle Ray-Coquard, Jérôme Fayette, et al.
European Journal of Cancer (Oxford, England : 1990)|January 27, 2020
Support of a molecular tumour board by an evidence-based decision management system for precision oncologyMario Lamping, Manuela Benary, Serge Leyvraz, et al.
The Oncologist|June 17, 2024
A diagnostic challenge of KIT p.V559D and BRAF p.G469A mutations in a paragastric massStefan Habringer, Jana Ihlow, Karsten Kleo, et al.
Cancer|January 10, 2018
Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07)Michael Montemurro, Angela Cioffi, Julien Dômont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2014
Adjuvant radiotherapy for extremity and trunk wall atypical lipomatous tumor/well-differentiated LPS (ALT/WD-LPS): a French Sarcoma Group (GSF-GETO) studyP A Cassier, G Kantor, S Bonvalot, et al.
Journal for Immunotherapy of Cancer|June 6, 2024
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanomaJoseph J Sacco, Richard D Carvajal, Marcus O Butler, et al.
European Journal of Endocrinology|March 25, 2022
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinomaSteven G Waguespack, Alexander Drilon, Jessica J Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2012
Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor eraPhilippe A Cassier, Elena Fumagalli, Piotr Rutkowski, et al.
Pageof 41